title: Can corticosteroids be beaten in future asthma therapy?
abstract: Despite the enormous therapeutic advance, there is a general trend towards increasing morbidity and mortality due to asthma, which suggests that there is a need for new and improved treatments. The past decade was determined by the so-called "new biology" that identified and cloned almost all receptors and ion channels. This scientific revolution should lead to a more rapid identification of novel targets for major diseases and processes like high throughput screening and combinatorial chemistry should have improved and fastened the development of new drugs. Interestingly, exactly the opposite has happened. With the exception of leukotriene receptor antagonists and some monoclonal antibodies, no new developments have been introduced into asthma therapy during the last decade. The most promising approach is still to find drugs like corticosteroids with multiple functions. However, there is no evidence at the very moment that corticosteroids can be beaten in the next ten years. Therefore, our task is to improve the corticosteroids and make therapy with them even safer. The so-called soft-steroids such as loteprednol and etiprednol belong to the future promising therapeutically effective and safe treatments of allergic disorders.
authors.affiliation: Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuernberg, Erlangen, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Amon
authors.forename: A
authors.initials: A
authors.lastname: Pahl
authors.forename: I
authors.initials: I
authors.lastname: Szelenyi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000737:chemistry / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D018836:Inflammation Mediators